We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Kymera Therapeutics Inc
3 watching
Current Price
$35.48
$-1.29
(-3.51%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,942.58M
52-Week High
46.22
52-Week Low
13.15
Average Volume
0.49M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,942.58M52-Week High46.2252-Week Low13.15Average Volume0.49MDividend Yield--P/E Ratio--What does the Kymera Therapeutics Inc do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Read More
How much money does Kymera Therapeutics Inc make?
News & Events about Kymera Therapeutics Inc.
Globe Newswire
24days ago
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the Company will present at the 41st Annual J.P...
Ticker Report
1month ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) Director Bruce Booth sold 378,966 shares of the companys stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $31.37, for a total transaction of $11,888,163.42. Following the completion of...
Ticker Report
1month ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) major shareholder Venture Fund X. L.P. Atlas sold 296,077 shares of the stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $31.37, for a total transaction of $9,287,935.49. Following the sale, the ...
Zolmax
1month ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) major shareholder Venture Fund X. L.P. Atlas sold 296,077 shares of the stock in a transaction on Wednesday, December 14th. The stock was sold at an average price of $31.37, for a total transaction of $9,287,935.49. Following the sale, the insider ...
Zolmax
1month ago
Kymera Therapeutics, Inc. (NASDAQ:KYMR Get Rating) shares gapped up before the market opened on Wednesday after SVB Leerink raised their price target on the stock from $26.00 to $31.00. The stock had previously closed at $25.85, but opened at $33.46. SVB Leerink currently has a market perform rating...
Frequently Asked Questions
Frequently Asked Questions
What is Kymera Therapeutics Inc share price today?
Can Indians buy Kymera Therapeutics Inc shares?
How can I buy Kymera Therapeutics Inc shares from India?
Can Fractional shares of Kymera Therapeutics Inc be purchased?
What are the documents required to start investing in Kymera Therapeutics Inc stocks?
What is today’s traded volume of Kymera Therapeutics Inc?
What is today’s market capitalisation of Kymera Therapeutics Inc?
What is the 52-Week High and Low Range of Kymera Therapeutics Inc?
What percentage is Kymera Therapeutics Inc down from its 52-Week High?
What percentage is Kymera Therapeutics Inc up from its 52-Week Low?
Current Price
$35.48
$-1.29
(-3.51%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.